US009511060B2

(12) **United States Patent**
Bachovchin et al.

(10) **Patent No.: US 9,511,060 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **NON-FLUSHING NIACIN ANALOGUES, AND METHODS OF USE THEREOF**

(71) Applicant: **Trustees of Tufts College**, Boston, MA (US)

(72) Inventors: **William W. Bachovchin**, Cambridge, MA (US); **Hung-sen Lai**, Andover, MA (US)

(73) Assignee: **Trustees of Tufts College**, Boston, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/932,506**

(22) Filed: **Nov. 4, 2015**

(65) **Prior Publication Data**

US 2016/0151343 A1 Jun. 2, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/514,995, filed on Oct. 15, 2014, now Pat. No. 9,193,708, which is a continuation of application No. 13/715,242, filed on Dec. 14, 2012, now Pat. No. 8,889,720, which is a continuation of application No. 12/376,238, filed as application No. PCT/US2007/074960 on Aug. 1, 2007, now Pat. No. 8,377,971.

(60) Provisional application No. 60/835,194, filed on Aug. 3, 2006.

(51) **Int. Cl.**

C07D 213/55	(2006.01)
C07D 213/80	(2006.01)
C07D 401/06	(2006.01)
A61K 31/44	(2006.01)
A61K 31/4439	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/4439*** (2013.01); ***A61K 45/06*** (2013.01); ***C07D 213/55*** (2013.01); ***C07D 213/80*** (2013.01); ***C07D 401/06*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,388,317	A	6/1983	Brown	
4,444,775	A	4/1984	Ford	
5,352,684	A	10/1994	Zimmermann et al.	
6,462,047	B1	10/2002	Bombrun et al.	
8,377,971	B2 *	2/2013	Bachovchin	C07D 213/55 514/340
8,889,720	B2 *	11/2014	Bachovchin	C07D 213/55 514/340
9,193,708	B2 *	11/2015	Bachovchin	C07D 213/55
2005/0222151	A1	10/2005	Carruthers et al.	

FOREIGN PATENT DOCUMENTS

EP	0013153	A1	7/1980
EP	1445250	A1	8/2004
JP	2006/056884	A	3/2006
JP	2009/520851	A	5/2009
JP	2009-520851	A	5/2009
JP	2009/544616	A	12/2009
WO	WO-00/15639	A1	3/2000
WO	WO-03/028724	A1	4/2003
WO	WO 03/028724	A1 *	4/2003
WO	WO-2004/064721	A2	8/2004
WO	WO-2006/121719	A2	11/2006
WO	WO-2006/122011	A2	11/2006

OTHER PUBLICATIONS

Isoda, S. et al., "Medicinal Chemical Studies on Antiplasmin Drugs. VI. Aza Analogs of 4-Aminomethylbenzoic Acid," *Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan* 28(5): 1408-1414 (1980).

Kato, K. et al., "Thromboxane Synthetase Inhibitors (TXSI). Design, Synthesis and Evaluation of a Novel Series of ω-Pyridylalkenoic Acids," *Journal of Medicinal Chemistry,* 28(3): 287-294 (1985).

Moradei, O. et al., "Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and Their Analogues: Novel Classes of Histone Deacetylase Inhibitors," *Bioorganic Medicinal Chemistry Letters* 16:4048-4052 (2006).

Schobert, R. et al.," cis-Dicloroplatinum (II) complexes with aminomethylnicotinate and -isonicotinate ligands," *Inorganica Chimica Acta,* 358(12): 3369-3376 (2005).

Scopes, D. et al., "New Kappa Receptor Agonists Based Upon a 2-[(alkylamino)methyl]piperidine Nucleus," *Journal of Medicinal Chemistry* 35(3): 490-501 (1992).

International Search Report for PCT/US2007/074960 mailed Sep. 22, 2008.

Office Action from corresponding Mexican application No. MX/a/2009/001279 dated Apr. 1, 2013.

Office Action from corresponding Japanese application No. 2009-523035 dated Oct. 16, 2012.

Supplementary European Search Report for European Patent Application No. 07 79 9967 dated Feb. 10, 2010.

* cited by examiner

Primary Examiner — Zinna Northington Davis
(74) *Attorney, Agent, or Firm* — Foley Haug LLP

(57) **ABSTRACT**

One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

23 Claims, 3 Drawing Sheets